Diethylcarbamazine

Overview

An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.

Indication

Used for the treatment of certain filarial diseases, including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.

Associated Conditions

Filarial Infection
Onchocerciasis

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Moxidectin for LF, Cote d'Ivoire (DOLF)	2020/06/01	NCT04410406	Phase 3	Active, not recruiting	Washington University School of Medicine
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )	2018/09/18	NCT03676140	Phase 3	Completed	Lihir Medical Centre
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )	2018/09/10	NCT03664063	Phase 2	Completed	Lihir Medical Centre
Lymphatic Filariasis (LF) in Ivory Coast	2016/11/28	NCT02974049	Not Applicable	Completed	University Hospitals Cleveland Medical Center
Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)	2016/07/27	NCT02845713	Phase 1	Completed	University Hospitals Cleveland Medical Center
Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection	2013/12/09	NCT02005653	Phase 4	Completed	Indian Council of Medical Research
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa	2013/11/03	NCT01975441	Phase 2	Completed	University Hospitals Cleveland Medical Center
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis	2013/07/23	NCT01905423	N/A	Completed	Washington University School of Medicine
Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis	2012/05/08	NCT01593722	Phase 4	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis	2010/04/27	NCT01111305	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
HETRAZAN TAB 50MG	lederle cyanamid canada inc.	00040819	Tablet - Oral	50 MG / TAB	5/31/1982

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access